{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:veristat-q131986594-answer-aa510bdb0ccf031ed5bb","key":"buyer_question:veristat-q131986594-answer-aa510bdb0ccf031ed5bb","kind":"buyer_question","slug":"veristat-q131986594-answer-aa510bdb0ccf031ed5bb","canonicalUrl":"https://readyscan.ai/corpus/buyer-question/veristat-q131986594-answer-aa510bdb0ccf031ed5bb","machineUrl":"https://readyscan.ai/discovery/corpus/buyer-question/veristat-q131986594-answer-aa510bdb0ccf031ed5bb.json","datePublished":"2026-10-25","dateModified":"2026-10-25","materialFingerprint":"fnv1a64:f0903d8f5fa017a0","membershipFingerprint":"fnv1a64:85a7c038071c850f","relatedEntitySlugs":["veristat-q131986594"],"relatedSurfaceKeys":["buyer_question:veristat-q131986594-answer-1a02751483e69f2ab788","buyer_question:veristat-q131986594-answer-3412882f879455f677e8","buyer_question:veristat-q131986594-answer-34458a603e1bff48200e","buyer_question:veristat-q131986594-answer-39b32ed129c8622469be","buyer_question:veristat-q131986594-answer-518eadbfcb69743d223e","buyer_question:veristat-q131986594-answer-5fbc154d4b1ba432fb13","buyer_question:veristat-q131986594-answer-6212fedf973f6b93dd9b","buyer_question:veristat-q131986594-answer-68df9892211ef7060c6a","buyer_question:veristat-q131986594-answer-c4405cf9ec71555384b3","buyer_question:veristat-q131986594-answer-cfd6628316e7e985c4b7","buyer_question:veristat-q131986594-answer-fe587a9c2de404de4138","evidence:veristat-q131986594"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"veristat-q131986594-content-20eafb8411341c3d-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q131986594","sourceRevisionId":"Q131986594:content:b79eadc27cef7bcc","sourceContentHash":"fnv1a64:1dce5caf659418af","recordRevisionId":"Q131986594:content:b79eadc27cef7bcc","recordContentHash":"fnv1a64:b2a53c98a2b6b9ea","sourceCanonicalUrl":"https://www.veristat.com/","sourceModifiedAt":"2026-10-25T07:29:48.087Z","observedOn":"2026-10-25","permission":{"basis":"public_information","evidenceUrl":"https://www.veristat.com/"},"attributionUrl":"https://www.veristat.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"What role do medical affairs experts play in clinical trial planning?","summary":"Cited source answers across 1 active corpus record.","question":"What role do medical affairs experts play in clinical trial planning?","answers":[{"entitySlug":"veristat-q131986594","entityName":"Veristat","answer":"“Medical affairs experts provide medical and safety input into development plans, protocol design, feasibility, site selection, and Key Opinion Leader identification, working alongside clinical operations and biometrics teams from the earliest planning stages.”","sourceUrls":["https://www.veristat.com/medical-affairs-and-patient-safety-expertise"]}]}